Advancements in the Clinical Use of Antidepressants for Adolescent Depression

Haoran XING; Xi ZHANG; Yingying ZHANG; Tianhao BAO

doi:10.12259/j.issn.2095-610X.S20240725

Volume 45 Issue 7

Jul. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2024 > 45(7): 168-176

Haoran XING, Xi ZHANG, Yingying ZHANG, Tianhao BAO. Advancements in the Clinical Use of Antidepressants for Adolescent Depression[J]. Journal of Kunming Medical University, 2024, 45(7): 168-176. doi: 10.12259/j.issn.2095-610X.S20240725

Citation:

Haoran XING, Xi ZHANG, Yingying ZHANG, Tianhao BAO. Advancements in the Clinical Use of Antidepressants for Adolescent Depression[J]. Journal of Kunming Medical University, 2024, 45(7): 168-176. doi: 10.12259/j.issn.2095-610X.S20240725

Citation:

PDF( 613 KB)

Advancements in the Clinical Use of Antidepressants for Adolescent Depression

doi: 10.12259/j.issn.2095-610X.S20240725

The Mental Health Center Affiliated to Kunming Medical University/ Science and Education Department，The Mental Hospital of Yunnan，Kunming Yunnan 650224，China

Received Date: 2023-11-16
Available Online: 2024-06-14
Publish Date: 2024-07-25

Abstract

Abstract

Compared with adult patients with depression, adolescents with depression have a higher incidence rate, poorer quality of life and poorer treatment effects. International guidelines generally recommend giving priority to psychological treatment for mild adolescent depression. For moderate to severe patients, antidepressant drugs combined with psychotherapy are a feasible option. How to choose suitable antidepressant drugs is still a problem to be solved. Antidepressant drugs have a series of side effects, including sleep disorders, extrapyramidal reactions, and gastrointestinal reactions. In order to reduce these side effects and improve clinical efficacy, individualized treatment plans are crucial. This article summarizes the pathogenesis of adolescent depression, the pharmacokinetics and side effects of antidepressant drugs, as well as the medication guidelines for adolescent patients with depression from 2013 to 2023, and provides scientific suggestions for drug treatment options for adolescent patients with depression.
- Adolescent,
- Depression,
- Antidepressive agents,
- Pharmacokinetics,
- Efficacy,
- Side effects

FullText(HTML)

References(79)

References

[1]	Liu W,Li G,Wang C,et al. Efficacy of sertraline combined with cognitive behavioral therapy for adolescent depression: A systematic review and meta-analysis[J]. Comput Math Methods Med,2021,2021:5309588.
[2]	Shorey S,Ng E D,Wong C. Global prevalence of depression and elevated depressive symptoms among adolescents: A systematic review and meta-analysis[J]. Br J Clin Psychol,2022,61(2):287-305. doi: 10.1111/bjc.12333
[3]	Avenevoli S,Swendsen J,He J P,et al. Major depression in the national comorbidity survey-adolescent supplement: Prevalence,correlates,and treatment[J]. J Am Acad Child Adolesc Psychiatry,2015,54(1): 37-44. e2.
[4]	Johnson D,Dupuis G,Piche J,et al. Adult mental health outcomes of adolescent depression: A systematic review[J]. Depress Anxiety,2018,35(8):700-716. doi: 10.1002/da.22777
[5]	Lee K H,Shin J,Lee J,et al. Measures of connectivity and dorsolateral prefrontal cortex volumes and depressive symptoms following treatment with selective serotonin reuptake inhibitors in adolescents[J]. JAMA Netw Open,2023,6(8):e2327331. doi: 10.1001/jamanetworkopen.2023.27331
[6]	Li C,Xu P,Huang Y,et al. RNA methylations in depression,from pathological mechanism to therapeutic potential[J]. Biochem Pharmacol,2023,215:115750. doi: 10.1016/j.bcp.2023.115750
[7]	Shao S L,Liu D Q,Zhang B,et al. Inflammatory response,a key pathophysiological mechanism of obesity-induced depression[J]. Mediators Inflamm,2020,2020:8893892.
[8]	Egeland M,Zunszain P A,Pariante C M. Molecular mechanisms in the regulation of adult neurogenesis during stress[J]. Nat Rev Neurosci,2015,16(4):189-200. doi: 10.1038/nrn3855
[9]	Jesulola E,Micalos P,Baguley I J. Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model - are we there yet?[J]. Behav Brain Res,2018,341:79-90. doi: 10.1016/j.bbr.2017.12.025
[10]	Liu Y,Wu Z,Cheng L,et al. The role of the intestinal microbiota in the pathogenesis of host depression and mechanism of TPs relieving depression[J]. Food Funct,2021,12(17):7651-7663. doi: 10.1039/D1FO01091C
[11]	Barnett R. Depression[J]. Lancet,2019,393(10186):2113. doi: 10.1016/S0140-6736(19)31151-1
[12]	Lu J,Xu X,Huang Y,et al. Prevalence of depressive disorders and treatment in China: A cross-sectional epidemiological study[J]. Lancet Psychiatry,2021,8(11):981-990. doi: 10.1016/S2215-0366(21)00251-0
[13]	LeMoult J,Chen M C,Foland-Ross L C,et al. Concordance of mother-daughter diurnal cortisol production: Understanding the intergenerational transmission of risk for depression[J]. Biol Psychol,2015,108:98-104. doi: 10.1016/j.biopsycho.2015.03.019
[14]	Asarnow L D. Depression and sleep: What has the treatment research revealed and could the HPA axis be a potential mechanism?[J]. Curr Opin Psychol,2020,34:112-116. doi: 10.1016/j.copsyc.2019.12.002
[15]	Sałaciak K,Pytka K. Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders[J]. Neurosci Biobehav Rev,2022,132:1114-1136. doi: 10.1016/j.neubiorev.2021.10.037
[16]	Colich N L,McLaughlin K A. Accelerated pubertal development as a mechanism linking trauma exposure with depression and anxiety in adolescence[J]. Curr Opin Psychol,2022,46:101338. doi: 10.1016/j.copsyc.2022.101338
[17]	Rodman A M,Vidal Bustamante C M,Dennison M J,et al. A year in the social life of a teenager: Within-person fluctuations in stress,phone communication,and anxiety and depression[J]. Clin Psychol Sci,2021,9(5):791-809. doi: 10.1177/2167702621991804
[18]	Cheng Z,Su J,Zhang K,et al. Epigenetic mechanism of early life stress-induced depression: Focus on the neurotransmitter systems[J]. Front Cell Dev Biol,2022,10:929732. doi: 10.3389/fcell.2022.929732
[19]	Kang B,Li Y,Zhao X,et al. Negative parenting style and depression in adolescents: A moderated mediation of self-esteem and perceived social support[J]. J Affect Disord,2024,345:149-156. doi: 10.1016/j.jad.2023.10.132
[20]	O'Callaghan G,Stringaris A. Reward processing in adolescent depression across neuroimaging modalities[J]. Z Kinder Jugendpsychiatr Psychother,2019,47(6):535-541. doi: 10.1024/1422-4917/a000663
[21]	Mao N,Che K,Chu T,et al. Aberrant resting-state brain function in adolescent depression[J]. Front Psychol,2020,11:1784. doi: 10.3389/fpsyg.2020.01784
[22]	Cheung A H,Zuckerbrot R A,Jensen P S,et al. Guidelines for adolescent depression in primary care (GLAD-PC): II. Treatment and ongoing management[J]. Pediatrics,2007,120(5):e1313-1326. doi: 10.1542/peds.2006-1395
[23]	Safer D J,Zito J M. Short- and long-term antidepressant clinical trials for major depressive disorder in youth: Findings and concerns[J]. Front Psychiatry,2019,10:705.
[24]	Bauer M,Severus E,Köhler S,et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: Maintenance treatment of major depressive disorder-update 2015[J]. World J Biol Psychiatry,2015,16(2):76-95. doi: 10.3109/15622975.2014.1001786
[25]	Seo J S,Bahk W M,Woo Y S,et al. Korean medication algorithm for depressive disorder 2021,fourth revision: An executive summary[J]. Clin Psychopharmacol Neurosci,2021,19(4):751-772. doi: 10.9758/cpn.2021.19.4.751
[26]	Sakurai H,Uchida H,Kato M,et al. Pharmacological management of depression: Japanese expert consensus[J]. J Affect Disord,2020,266:626-632. doi: 10.1016/j.jad.2020.01.149
[27]	Bennabi D,Charpeaud T,Yrondi A,et al. Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts,the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental[J]. BMC Psychiatry,2019,19(1):262. doi: 10.1186/s12888-019-2237-x
[28]	Kennedy S H,Lam R W,McIntyre R S,et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments[J]. Can J Psychiatry,2016,61(9):540-560. doi: 10.1177/0706743716659417
[29]	Meyer A E,Curry J F. Moderators of treatment for adolescent depression[J]. J Clin Child Adolesc Psychol,2021,50(4):486-497. doi: 10.1080/15374416.2020.1796683
[30]	Summary of the clinical practice guideline for the treatment of depression across three age cohorts[J]. Am Psychol,2022,77(6): 770-780.
[31]	Luxton R,Kyriakopoulos M. Depression in children and young people: identification and management NICE guidelines[J]. Arch Dis Child Educ Pract Ed,2022,107(1):36-38.
[32]	Malhi G S,Bell E,Bassett D,et al. The 2020 royal australian and new zealand college of psychiatrists clinical practice guidelines for mood disorders[J]. Aust N Z J Psychiatry,2021,55(1):7-117. doi: 10.1177/0004867420979353
[33]	中华医学会行为医学分会,中华医学会行为医学分会认知应对治疗学组. 抑郁症治疗与管理的专家推荐意见(2022年)[J]. 中华行为医学与脑科学杂志,2023,32(3):193-202. doi: 10.3760/cma.j.cn371468-20220921-00563
[34]	Murphy S E,Capitão L P,Giles S,et al. The knowns and unknowns of SSRI treatment in young people with depression and anxiety: Efficacy,predictors,and mechanisms of action[J]. Lancet Psychiatry,2021,8(9):824-835. doi: 10.1016/S2215-0366(21)00154-1
[35]	Ethical principles of psychologists and code of conduct[J]. Am Psychol,2002,57(12): 1060-1073.
[36]	Zhou X,Teng T,Zhang Y,et al. Comparative efficacy and acceptability of antidepressants,psychotherapies,and their combination for acute treatment of children and adolescents with depressive disorder: A systematic review and network meta-analysis[J]. Lancet Psychiatry,2020,7(7):581-601. doi: 10.1016/S2215-0366(20)30137-1
[37]	Hetrick S E,McKenzie J E,Cox G R,et al. Newer generation antidepressants for depressive disorders in children and adolescents[J]. Cochrane Database Syst Rev,2012,11(11):CD004851.
[38]	Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association[J]. Am J Psychiatry,2000,157(4 Suppl): 1-45.
[39]	Millan M J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates,drug discovery and therapeutic application[J]. Pharmacol Ther,2006,110(2):135-370. doi: 10.1016/j.pharmthera.2005.11.006
[40]	Rojo J E,Ros S,Agüera L,et al. Combined antidepressants: clinical experience[J]. Acta Psychiatr Scand Suppl,2005(428):25-31,36.
[41]	Blier P,Gobbi G,Turcotte J E,et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation[J]. Eur Neuropsychopharmacol,2009,19(7):457-465. doi: 10.1016/j.euroneuro.2009.01.015
[42]	Gibbons R D,Brown C H,Hur K,et al. Suicidal thoughts and behavior with antidepressant treatment: Reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine[J]. Arch Gen Psychiatry,2012,69(6):580-587. doi: 10.1001/archgenpsychiatry.2011.2048
[43]	Carpenter D J,Fong R,Kraus J E,et al. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: A complete set of randomized placebo-controlled trials[J]. J Clin Psychiatry,2011,72(11):1503-1514. doi: 10.4088/JCP.08m04927blu
[44]	Rushton J L,Clark S J,Freed G L. Pediatrician and family physician prescription of selective serotonin reuptake inhibitors[J]. Pediatrics,2000,105(6):E82. doi: 10.1542/peds.105.6.e82
[45]	Brent D,Emslie G,Clarke G,et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial[J]. JAMA,2008,299(8):901-913. doi: 10.1001/jama.299.8.901
[46]	Cheung A,Kusumakar V,Kutcher S,et al. Maintenance study for adolescent depression[J]. J Child Adolesc Psychopharmacol,2008,18(4):389-394. doi: 10.1089/cap.2008.0001
[47]	Emslie G J,Kennard B D,Mayes T L,et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents[J]. Am J Psychiatry,2008,165(4):459-467. doi: 10.1176/appi.ajp.2007.07091453
[48]	Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants[J]. Expert Opin Drug Metab Toxicol,2019,15(10):831-847. doi: 10.1080/17425255.2019.1669560
[49]	Bousman C A,Stevenson J M,Ramsey L B,et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6,CYP2C19,CYP2B6,SLC6A4,and HTR2A genotypes and serotonin reuptake inhibitor antidepressants[J]. Clin Pharmacol Ther,2023,114(1):51-68. doi: 10.1002/cpt.2903
[50]	喻东山,葛茂宏. 精神科合理用药手册(第2版)[M]. 南京:江苏科学技术出版社,2011:132-151.
[51]	Preskorn S H. Drug-drug interactions (DDIs) in psychiatric practice,part 8: Relative receptor binding affinity as a way of understanding the differential pharmacology of currently available antidepressants[J]. J Psychiatr Pract,2020,26(1):46-51. doi: 10.1097/PRA.0000000000000445
[52]	Margolis J M,O'Donnell J P,Mankowski D C,et al. (R)-,(S)-,and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes[J]. Drug Metab Dispos,2000,28(10):1187-1191.
[53]	Jornil J,Jensen K G,Larsen F,et al. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator[J]. Drug Metab Dispos,2010,38(3):376-385. doi: 10.1124/dmd.109.030551
[54]	Hiemke C,Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors[J]. Pharmacol Ther,2000,85(1):11-28. doi: 10.1016/S0163-7258(99)00048-0
[55]	Mandrioli R,Mercolini L,Raggi M A. Evaluation of the pharmacokinetics,safety and clinical efficacy of sertraline used to treat social anxiety[J]. Expert Opin Drug Metab Toxicol,2013,9(11):1495-1505. doi: 10.1517/17425255.2013.816675
[56]	Mrazek D A,Biernacka J M,O'Kane D J,et al. CYP2C19 variation and citalopram response[J]. Pharmacogenet Genomics,2011,21(1):1-9. doi: 10.1097/FPC.0b013e328340bc5a
[57]	Zastrozhin M,Skryabin V,Smirnov V,et al. Effect of genetic polymorphism of the CYP2D6 gene on the efficacy and safety of fluvoxamine in major depressive disorder[J]. Am J Ther,2021,29(1):e26-e33.
[58]	Karlsson L,Zackrisson A L,Josefsson M,et al. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases[J]. Pharmacogenomics J,2015,15(2):165-171. doi: 10.1038/tpj.2014.50
[59]	Knadler M P,Lobo E,Chappell J,et al. Duloxetine: Clinical pharmacokinetics and drug interactions[J]. Clin Pharmacokinet,2011,50(5):281-294. doi: 10.2165/11539240-000000000-00000
[60]	Hazell P. Antidepressants in adolescence[J]. Aust Prescr,2022,45(2):49-52. doi: 10.18773/austprescr.2022.011
[61]	Kloosterboer S M,Vierhout D,Stojanova J,et al. Psychotropic drug concentrations and clinical outcomes in children and adolescents: A systematic review[J]. Expert Opin Drug Saf,2020,19(7):873-890. doi: 10.1080/14740338.2020.1770224
[62]	Cipriani A,Zhou X,Del Giovane C,et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: A network meta-analysis[J]. Lancet,2016,388(10047):881-890. doi: 10.1016/S0140-6736(16)30385-3
[63]	Foster S,Mohler-Kuo M. Treating a broader range of depressed adolescents with combined therapy[J]. J Affect Disord,2018,241:417-424. doi: 10.1016/j.jad.2018.08.027
[64]	Strawn J R,Mills J A,Poweleit E A,et al. Adverse effects of antidepressant medications and their management in children and adolescents[J]. Pharmacotherapy,2023,43(7):675-690. doi: 10.1002/phar.2767
[65]	Strawn J R,Dobson E T,Giles L L. Primary pediatric care psychopharmacology: Focus on medications for ADHD,depression,and anxiety[J]. Curr Probl Pediatr Adolesc Health Care,2017,47(1):3-14. doi: 10.1016/j.cppeds.2016.11.008
[66]	David D J,Gourion D. Antidepressant and tolerance: Determinants and management of major side effects[J]. Encephale,2016,42(6):553-561. doi: 10.1016/j.encep.2016.05.006
[67]	Revet A,Montastruc F,Roussin A,et al. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database[J]. BMC Psychiatry,2020,20(1):308. doi: 10.1186/s12888-020-02711-z
[68]	Shelton R C. Serotonin and norepinephrine reuptake inhibitors[J]. Handb Exp Pharmacol,2019,250:145-180.
[69]	Nestler E J,Carlezon W A Jr. The mesolimbic dopamine reward circuit in depression[J]. Biol Psychiatry,2006,59(12):1151-1159. doi: 10.1016/j.biopsych.2005.09.018
[70]	Bridge J A,Iyengar S,Salary C B,et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials[J]. JAMA,2007,297(15):1683-1696. doi: 10.1001/jama.297.15.1683
[71]	Ignaszewski M J,Waslick B. Update on randomized placebo-controlled trials in the past decade for treatment of major depressive disorder in child and adolescent patients: A Systematic Review[J]. J Child Adolesc Psychopharmacol,2018,28(10):668-675. doi: 10.1089/cap.2017.0174
[72]	Hirschfeld R M. Differential diagnosis of bipolar disorder and major depressive disorder[J]. J Affect Disord,2014,169 (Suppl 1): S12-16.
[73]	Rochoy M,Zakhem-Stachera C,Béné J,et al. Antidepressive agents and hyponatremia: A literature review and a case/non-case study in the French pharmacovigilance database[J]. Therapie,2018,73(5):389-398. doi: 10.1016/j.therap.2018.02.006
[74]	Richa S,Yazbek J C. Ocular adverse effects of common psychotropic agents: A review[J]. CNS Drugs,2010,24(6):501-526. doi: 10.2165/11533180-000000000-00000
[75]	Skop B P,Brown T M. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors[J]. Psychosomatics,1996,37(1):12-16. doi: 10.1016/S0033-3182(96)71592-X
[76]	Funk K A,Bostwick J R. A comparison of the risk of QT prolongation among SSRIs[J]. Ann Pharmacother,2013,47(10):1330-1341. doi: 10.1177/1060028013501994
[77]	Voican C S,Corruble E,Naveau S,et al. Antidepressant-induced liver injury: A review for clinicians[J]. Am J Psychiatry,2014,171(4):404-415. doi: 10.1176/appi.ajp.2013.13050709
[78]	Blumberger D M,Vila-Rodriguez F,Wang W,et al. A randomized sham controlled comparison of once vs twice-daily intermittent theta burst stimulation in depression: A Canadian rTMS treatment and biomarker network in depression (CARTBIND) study[J]. Brain Stimul,2021,14(6):1447-1455. doi: 10.1016/j.brs.2021.09.003
[79]	Borbély É,Simon M,Fuchs E,et al. Novel drug developmental strategies for treatment-resistant depression[J]. Br J Pharmacol,2022,179(6):1146-1186. doi: 10.1111/bph.15753

Relative Articles(20)

Relative Articles

[1]	Xiangjing SONG, Shaojie YANG, Kejian WANG, Yuzhi LAN, Cai KONG, Tao WANG, Changcui WU. Growth and Development of Adolescent Girls of Lahu Ethnic Group in Lancang County of Yunnan Province. Journal of Kunming Medical University, 2023, 44(6): 33-39. doi: 10.12259/j.issn.2095-610X.S20230619
[2]	Ling ZHAO, Shulan JIAO, Yongyu SI, Liu YANG, Yinghui BU. Pharmacokinetic Study of Dexmedetomidine in Patients with Different Degrees of Burn. Journal of Kunming Medical University, 2023, 44(7): 100-104. doi: 10.12259/j.issn.2095-610X.S20230725
[3]	Zhaosong CHU, Xin WANG, Mengxin HE, Xiufeng XU, Na WANG, Zonglin SHEN. Research Progress on Gene Related to Suicide in Major Depressive Disorder：A Review. Journal of Kunming Medical University, 2023, 44(3): 143-148. doi: 10.12259/j.issn.2095-610X.S20230301
[4]	Lei YU, Wenzhi WU, Yunqiao ZHANG, Xu YOU, Yong ZENG. Research Overview of HPA Axis in Depression. Journal of Kunming Medical University, 2023, 44(2): 166-171. doi: 10.12259/j.issn.2095-610X.S20230222
[5]	Deng'ai DUAN, Yonghui ZHANG, Wei WANG, Xinju LIAO, Zhixiong ZHANG. Effect of Childhood Abuse on Non-suicidal Self-injury in Adolescents with First-episode Depression. Journal of Kunming Medical University, 2023, 44(3): 120-124. doi: 10.12259/j.issn.2095-610X.S20230304
[6]	Feng YUANG, Shu-lan JIAO, Rui CHEN, Bing-bing XIANG, Yong-yu SI. Pharmacokinetics of Etomidate in Patients with Different Degrees of Burn. Journal of Kunming Medical University, 2021, 42(6): 94-97. doi: 10.12259/j.issn.2095-610X.S20210637
[7]	Xiao-yun WANG, Qiao-yun WANG, Ming-hua GU, Yu DING, Yu-wen GUANG, Ji-lan ZHANG. Mechanism of miR-373 on Behaviors of Depression-mice via P2X7R. Journal of Kunming Medical University, 2021, 42(10): 29-37. doi: 10.12259/j.issn.2095-610X.S20211030
[8]	Xing LIU, Bing OUYANG, Na LI, Ji LUO, Xu-qin SHI, Jie CHEN, Hui SUN, Hai-wen LI. Effect and Economic Evaluation of the Combination of Traditional Chinese and Western Medicine in Treatment of MDR-TB. Journal of Kunming Medical University, 2020, 41(11): 49-55. doi: 10.12259/j.issn.2095-610X.S20201106
[9]	Xian LI, Chang-liang JI, Shu-e ZENG, Shu-yun YANG, Hao-qi YANG, Ya-ting HOU. A Comparative Study of the Cognitive Function in Patients with Different Degrees of Depression. Journal of Kunming Medical University, 2020, 41(12): 94-98. doi: 10.12259/j.issn.2095-610X.S20201226
[10]	Liu Chang , Shen Zong Lin , Cheng Yu Qi , Xu Xiu Feng . . Journal of Kunming Medical University, 2019, 40(10): 160-164.
[11]	Jiao Feng , Yan Rui , Dong Zhe , Pu Juan , Han Fang . . Journal of Kunming Medical University, 2019, 40(12): 54-60.
[12]	Li Zun Hua , Wu Hong Xiang , Qiu Liang Wu , Li Jun . . Journal of Kunming Medical University, 2019, 40(11): 39-43.
[13]	Bao Wen Li . . Journal of Kunming Medical University,
[14]	Wang Ji Cai . . Journal of Kunming Medical University,
[15]	Du Ying Rong . . Journal of Kunming Medical University,
[16]	Tang Xiang Hui . . Journal of Kunming Medical University,
[17]	Li Chong Yang . Analysis of Related Factors of Treatment and Prognosis of Osteosarcoma in Adolescence. Journal of Kunming Medical University,
[18]	Wang Heng Chang . Risky Behavior Analysis Among Adolescents in a Certain District of a Certain City. Journal of Kunming Medical University,
[19]	Li Cong Mei . . Journal of Kunming Medical University,
[20]	Wang Ji Cai . . Journal of Kunming Medical University,